Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL

Online Only
Wayne Kuznar, Medical Writer
View additional articles by this author
Download PDF

Front-line ibrutinib therapy results in a lower rate of disease progression or death than the current standard-of-care chemoimmunotherapy with bendamustine and rituximab in older patients with chronic lymphocytic leukemia (CLL). Adding rituximab to ibrutinib did not improve outcomes compared with ibrutinib alone, reported Jennifer A. Woyach, MD, Associate Professor, Ohio State University Comprehensive Cancer Center, Columbus, at ASH 2018.

Data from the international phase 3 clinical trial (Alliance A041202) of patients aged ≥65 years with newly diagnosed CLL demonstrated a 2-year ­estimate of progression-free survival (PFS) of 87% in patients randomized to ibrutinib alone and 88% in those randomized to ibrutinib plus rituximab versus 74% in patients in the bendamustine plus rituximab arm.

After a median follow-up of 38 months, the median PFS was 43 months in the bendamustine plus rituximab arm and had not been reached in the 2 ibrutinib­containing arms. No difference has yet emerged in overall survival (OS), which may be the result of crossover from the chemoimmunotherapy arm to an ibrutinib-containing regimen, as well as the short follow-up period, said Dr Woyach.

“At the time the study was designed, bendamustine-rituximab was widely used in the community based on excellent data in the phase 2 setting,” she said. “During this time, the BTK [Bruton’s tyrosine kinase] inhibitor ibrutinib was just entering the clinic. Despite now widespread use in the front-line following its FDA approval for this indication in 2016, the efficacy of ibrutinib versus standard chemoimmunotherapy had not previously been investigated.”

Ibrutinib, with or without rituximab, was compared with bendamustine­rituximab in 547 patients (median age, 71 years) with treatment-naïve, intermediate- or high-risk CLL. Overall, 54% of patients had high-risk disease, and 25% had high-risk cytogenetics—deletion (del)17p or del11q. Study participants were stratified according to disease risk (high or intermediate) and cytogenetics, and were randomized in a 1:1:1 ratio to 3 arms: arm A, bendamustine plus rituximab administered in six 28-day cycles (N = 183); arm B, oral ibrutinib (N = 182); and arm C, ibrutinib plus rituximab on days 1, 8, 15, and 22 of cycle 2, and on day 1 of cycles 3 to 6 (N = 182). Patients received treatment until disease progression or until unacceptable toxicity; patients randomized to arm A could cross over to arm B if their disease progressed.

Of the 547 patients, 96% were available for the primary PFS analysis. The 2-year PFS values translated to a lower risk of disease progression or death in the 2 ibrutinib-containing arms (hazard ratio, 0.39 for arm A vs arm B; 0.38 for arm A vs arm C; P <.001 for both). The median OS has not been reached in any arm. The 2-year OS estimates for bendamustine plus rituximab, ibrutinib alone, and ibrutinib plus rituximab are 95%, 90%, and 94%, respectively.

Grade ≥3 hematologic adverse events were more common in the chemoimmunotherapy group (61%) than in the ibrutinib-alone (41%) or ibrutinib plus rituximab group (38%). Overall, 40% of the bendamustine plus rituximab arm had grade ≥3 neutropenia compared with 15% to 21% of the ibrutinib-­containing arms. Grade ≥3 nonhematologic adverse events were more common in the ibrutinib-containing arms (74%) versus the chemoimmunotherapy arm (63%). Grade ≥3 hypertension was 29% in the ibrutinib-alone arm and 34% in the ibrutinib plus rituximab arm versus 15% in the bendamustine plus rituximab arm (P <.001). Atrial fibrillation was reported in up to 17% of patients who received ibrutinib.

Clinical Implications

“This really does indicate that ibrutinib as front-line therapy, which many clinicians have been doing, is a very reasonable practice,” commented David P. Steensma, MD, Institute Physician, Hematologic Oncology Treatment Center, Dana-Farber Cancer Institute, Boston.

Ongoing clinical trials are investigating more specific second-generation BTK inhibitors, with potentially better safety profiles, as well as novel combination therapies, such as venetoclax (Venclexta) plus ibrutinib, with or without obinutuzumab (Gazyva), that do not include chemotherapy. By using these new combinations “we try to intensify therapy earlier on, to try to get deeper remissions and therefore stop therapy,” Dr Woyach said. Limiting the duration of therapy may also be important to explore, she noted.

Related Items
Vyxeos Now Indicated for Pediatric Patients with AML
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Leukemia, Pediatric Cancer
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in From the Literature, Leukemia
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma
The Incidence of Arterial and Venous Thromboembolism in Patients with Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Who Are Treated with Ponatinib
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Leukemia, Thromboembolism
Optimizing Response to Enasidenib with Dose Escalation in Relapsed or Refractory Acute Myeloid Leukemia
Amany R. Keruakous, MD, Sarah A. Schmidt, PharmD, Marcus T. Autry, PharmD, Julia Ye, PharmD Candidate, Phoi Nguyen, PharmD Candidate, Silas Day
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in Case Report, Dose Escalation/Reduction, Leukemia
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelodysplastic Syndromes
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Graft-versus-Host-Disease
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, CAR T-Cell Therapy, Lymphoma
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.